
Using eClinical technologies to access vendor performance allows for researchers to choose appropriate vendors based on trial design, needs and risks. These decisions can be made using historical comparative data from a normative database.

Using eClinical technologies to access vendor performance allows for researchers to choose appropriate vendors based on trial design, needs and risks. These decisions can be made using historical comparative data from a normative database.

Worldwide Clinical Trials recently announced the results of a survey that evaluated the perceptions of clinical trial site investigators who use electronic clinical outcome assessment (eCOA) technologies.

Applied Clinical Trials
The data analysis in this article will delve into Clinical SCORE’s normative database to generate predictive models, and qualitatively reason the findings.

Applied Clinical Trials
Exploring three pivotal technology areas that could reshape global studies over the next 10 years.

This article explores the survey data to uncover opinions about traditional endpoint adjudication use (i.e., Excel, paper, emails, etc.) compared eClinical technologies to adjudicate events.

The Site Impact Survey was designed by Clinical Ink to evaluate clinical research coordinator and investigator experiences with Clinical Ink’s eSource system compared to paper source.

Applied Clinical Trials
In our latest webcast that aired live October 14, Oracle Health Sciences brought together three presenters from smaller or medium-size organizations in an effort to educate similar-sized companies on the benefits of EDC.

Applied Clinical Trials
Even with the rapid increase in clinical trials and demand for cloud-based systems, doing business in China is not easy if you are unfamiliar with the territory.

Applied Clinical Trials
Survey provides new benchmarks on e-solutions adoption, but actual impact data remains elusive.

Applied Clinical Trials
How to satisfy regulatory concerns about EDC data integrity and site controls over its source records.

Applied Clinical Trials
In clinical trials, the ability to effectively plan, collect and maintain essential clinical trial documentation is challenging.

Applied Clinical Trials
Last month, Veeva Systems unveiled the results of its 2015 Paperless TMF Survey: Annual Report. The survey is in its second year, and as Jennifer Goldsmith, vice president of Veeva Vault, told Applied Clinical Trials, it was interesting and significant to report on the year-over-year results.

Applied Clinical Trials
Understanding the roles of eTMF, CTMS, and study startup solutions in the clinical trials process

Applied Clinical Trials
eSource is not a new term. But eSource does seem to be getting a lot of attention lately.

Applied Clinical Trials
Historically, some longstanding challenges have hindered efforts to integrate patient data from EMRs (Electronic Medical Record systems) with EDC (Electronic Data Capture) systems.

Applied Clinical Trials
ERT’s announcement of its intention to acquire PHT makes more than sense. And when speaking with the companies’ CEOs, Jim Corrigan and Philip Lee respectively, the potential for success is greater than any challenges the current clinical trials market could throw their way.

Applied Clinical Trials
Combing for clinical trials patients and the best way to make the match between trial and patient is a multifaceted task.

Applied Clinical Trials
As we move towards cloud-based technologies, lingering questions and concerns remain.

Applied Clinical Trials
Take a look at past, present, and future clinical study processes and see how IRT/EDC unification increases study agility and efficiency while decreasing cost to sponsors.

Applied Clinical Trials
Does the emerging world still lag behind in EDC adoption?

Applied Clinical Trials

Applied Clinical Trials
Overcoming clinical research inefficiencies to improve trial outcomes.

Applied Clinical Trials
Efficiency and ease of use-bringing technologies together into a converged suite.

Applied Clinical Trials
Using interactive response technology to avoid unblinding in randomized controlled trials.
